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Ebola virus causes a lethal hemorrhagic disease for which no therapy or vaccine is currently approved. Re-
cently, the crystal structure of the Ebola virus glycoprotein in complex with a human neutralizing antibody
was illuminated, providing a path from the shadows toward understanding cellular attachment, viral fusion,
and immune evasion.Outbreaks of infection by Ebola virus
(EBOV) occur sporadically in primates
and humans in central Africa and cause
a hemorrhagic disease with 40 to 90%
lethality, usually within 1 to 2 weeks of ex-
posure (Zampieri et al., 2007). At least four
distinct strains of EBOV have been identi-
fied to date, which, along with the related
Marburg virus, are enveloped negative
polarity single-stranded RNA viruses that
constitute the Filoviridae family, so named
because of their long filamentous mor-
phology. The enzootic reservoir of these
viruses is now believed to be fruit bats,
which do not appear to suffer significant
pathology during infections. As EBOV in-
fection can spread rapidly through a com-
munity by direct contact with an infected
person or their body fluids, development
of antiviral agents or vaccines that can
be used in the postexposure setting is
an important and urgent goal.
The EBOV genome encodes seven
unique proteins, with the type I transmem-
brane glycoprotein (GP) serving as the
essential mediator of target cell attach-
ment, entry, and fusion. GP is expressed
in EBOV-infected cells as a highly glyco-
sylated 676 residue protein that is pro-
cessed by furin proteases after residue
501 into a 140 kDa N-terminal fragment
(GP1) and a 26 kDa C-terminal fragment
(GP2) that remain disulfide linked. Hetero-
dimers of GP1 and GP2 are tethered to
the viral membrane through the C-termi-
nal tail of GP2, and oligomerize into tri-
mers to form the 10 nm spikes that pro-
ject from the outer viral envelope, which is
40–50 nm in diameter and can stretch to
greater than 1000 nm in length. The GP1
fragment has been ascribed a primaryrole in target cell attachment and recep-
tor-mediated endocytosis, with GP2 play-
ing a critical role in viral membrane fusion
in endosomes. Earlier structural studies of
truncated EBOV GP2 fragments revealed
a core region that forms a trimer in which
a long three-stranded coiled coil created
by helical region 1 (denoted as the four
segments HR1A-D) is surrounded by
shorter C-terminal helices that are packed
in an antiparallel orientation (Malashke-
vich et al., 1999; Weissenhorn et al.,
1998). While this presumed postfusion
EBOV GP2 conformation loosely resem-
bles several other viral membrane-fusion
proteins, little was known about the as-
sembly or regulation of the prefusion GP.
In a recent issue of Nature, Lee and col-
leagues have shed significant light on
this subject by determining the crystal
structure of truncated fragments of the
EBOVGP1 andGP2 ectodomains in com-
plex with the KZ52 human monoclonal
antibody (mAb) (Lee et al., 2008).
The GP assembles as a trimer with
a deep bowl or cup-like configuration in
what is arguably the mature or pre-fusion
configuration found on the extracellular
virus (Lee et al., 2008) (Figure 1). EBOV
GP1 (residues 33–310) adopts an approx-
imately cylindrical shape that can be
architecturally divided into three subdo-
mains: (1) the N-terminal and mem-
brane-proximal base, which intimately
engages with GP2 segments including
an interchain disulfide bond; (2) the
head, created in part by base subdomain
insertions that project away fromGP2 and
the viral membrane; and (3) a glycan-rich
cap that adorns the head subdomain dis-
tal from the base. The EBOV-Zaire GP1Cell Host & Microbexpression construct used to facilitate
structural analysis lacks the C-terminal
mucin-like domain, and several other re-
gions could not be built in the low-resolu-
tion structure. The assembly of the GP
trimer is mediated predominantly via
GP2, which forms the inner core of the tri-
mer utilizing HR1D, while HR1C adopts
a turn that projects the helical HR1A and
HR1B segments to the outer surface of
the trimer, where they engage primarily
the GP1 base domain. In the postfusion
conformation, HR1 forms a single a helix
that acts as the core of the trimeric coiled
coil, with HR2 forming the outer bundle in
an antiparallel fashion. Here, the two-seg-
mented configuration of HR1 in the prefu-
sion trimer is held in a trigger-prone
conformation by elaborate interactions
with GP1, whereas the C-terminal regions
including HR2 that link GP2 to the viral
membrane are apparently disordered.
The hydrophobic fusion loop and flanking
b hairpin of GP2 unexpectedly resemble
those of flaviviruses, and play an impor-
tant role in trimer assembly by reaching
out and embedding into a niche in the
adjacent GP1 subunit.
GP1 residues previously implicated in
EBOV entry are localized to the base
and head subdomains, but surprisingly
only a limited number of these amino
acids have appreciable solvent accessi-
bility in the newly available structural
model. Indeed, many of these are deeply
buried hydrophobic residues that appear
to be important in the structural assembly
of the GP itself. Lee et al. (2008) suggest
that EBOV cellular attachment may be
facilitated by six highly conserved head
subdomain residues that cluster ine 4, August 14, 2008 ª2008 Elsevier Inc. 87
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PreviewsFigure 1. Structure of the EBOV GP Trimer in Complex with the KZ52 Fab
CPKmodels of the threeGP1 subunits of the assembly are displayed in shades of blue, while GP2 subunits
are shown in shades of magenta. The KZ52 Fab is depicted as a ribbon diagram with the light (VL) and
heavy chains (VH) colored light and dark gray, respectively. The six solvent exposed residues located in
each GP1 head subdomain within the bowl of the trimer that Lee et al. suggest may be a binding site
for the putative EBOV receptor are colored yellow (K114, K115, K140, G143, P146, and C147). In addition
to creating the core of the trimeric GP assembly (via HR1D), GP2 also forms a belt that wraps around its
entire circumference, with the internal fusion loop grasping onto adjacent subunits (GP2 residues 529–
535, shown in red).a recession under the glycan cap within
the bowl-shaped trimer and further that
that proteolytic removal of the glycan
cap and mucin domains could enhance
accessibility and augment cellular entry.
The structure of the GP trimer provides
new insight into the possible mechanisms
of EBOV fusion. Recent studies have indi-
cated that the low pH environment of the
endosome is necessary but not sufficient
for productive EBOV infection (Chandran
et al., 2005; White et al., 2008). Indeed,
examination of the GP trimer does not re-
veal any apparent regions that are poised
to undergo pH-dependent structural tran-
sitions, for instance clusters of histidine or
acidic residues thought to regulate other
viral membrane glycoprotein conforma-
tional changes (Harrison, 2008). An alter-
nate function of pH in triggering EBOV
fusion may be through the activation of
endosomal proteases and/or reductases
capable of modifying GP. Lee et al. (2008)
suggest that these covalent modifications
could promote rearrangement of GP2 and
membrane insertion of the fusion peptide,
which is otherwise packed into a niche
formed in the adjacent GP1 subunit of
the trimer.
The GP structure was determined in
complex with the antigen-binding frag-
ment (Fab) of the KZ52 monoclonal anti-
body that was isolated from a human88 Cell Host & Microbe 4, August 14, 2008 ªsurvivor of the 1995 Kikwit Zaire EBOV
outbreak. Three Fabs decorate the mem-
brane-proximal exterior of the trimer
through extensive GP2 contacts (N-termi-
nal residues 505–514 and 549–556) and
minor contacts with the base subdomain
of GP1 (residues 42–43). Of the 15GP res-
idues contacted by KZ52, ten are unique
to EBOV Zaire, and not surprisingly the
antibody has limited efficacy against
other EBOV isolates. Because KZ52
recognition requires both GP1 and GP2,
Lee et al. (2008) suggest that the antibody
may uniquely bind the prefusion confor-
mation. While the mechanism of EBOV
neutralization is currently unknown, the
authors speculate that KZ52 could pre-
vent the GP2 rearrangements required
for fusion, or alternatively, sterically hinder
undefined attachment and/or entry
processes.
For many viruses, the induction of a
robust neutralizing antibody response
against surface envelope or spike pro-
teins is associated with clearance from
circulation and improvement in clinical
outcome. However, for EBOV, because
of its rapid course of infection and evolu-
tion of specific mechanisms to delay, at-
tenuate, or prevent expedient humoral
responses, production of neutralizing an-
tibodies against GP during primary infec-
tion may not correlate with clearance or2008 Elsevier Inc.control (Mohamadzadeh et al., 2007;
Zampieri et al., 2007). EBOV mechanisms
of humoral immune evasion include ex-
tensive carbohydrate masking, primarily
in the membrane-distal glycan cap and
mucin domains of GP1 that the KZ52 an-
tibody capably avoids. Transcriptional
editing also produces an alternate, se-
creted form of GP that appears to adopt
a unique assembly that is immunodomi-
nant as assessed by antibody reactivity
from human EBOV survivors.
Because the antibody response to
EBOV is poor during the early phases of
natural infection, passive administration
of high-titer neutralizing anti-EBOV anti-
bodies has been proposed as a strategy
to mitigate disease. Antibody therapy in
experimental animals, unfortunately, has
not provided clear answers: protection
by neutralizing mAbs against lethal
EBOV infection in the guinea pig and
mouse has been convincingly demon-
strated; however, administration of KZ52
to nonhuman primates failed to alter the
course of EBOV infection (Wilson et al.,
2000; Oswald et al., 2007). The disparity
in antibody protection observed in the dif-
ferent animal models could reflect distinct
cellular tropisms, receptor affinities, or
differences in GP glycosylation or other
posttranslational modifications. More-
over, potentially species-unique immune
evasive roles of secreted EBOV GP to
decoy or misdirect the humoral immune
response are alternative possibilities.
Although antibodies against virion gly-
coproteins can protect against infection
through multiple mechanisms, including
the blockade of cellular attachment,
complement opsonization and/or lysis,
Fc-g receptor-mediated clearance, or
antibody-dependent cellular cytotoxicity,
potently neutralizing antibodies against
other enveloped viruses apparently also
have the capacity to inhibit post entry
membrane fusion events (Nybakken
et al., 2005). As endosomal fusion is
a common step downstream of multiple
attachment and entry pathways a given
virus may employ, the rare antibodies
that disrupt structural rearrangements
associated with fusion might comprise
a particularly potent class of inhibitors.
However, the requirement for endosomal
processing of EBOV provides an addi-
tional theoretical target for antibody
neutralization—the disruption of critical
enzymatic activities required for fusion,
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and L or perhaps the enzymatic reduction
of a critical disulfide bond.
Plato warned us in the Republic that
upon emerging from the cave of projected
shadows we might become overly daz-
zled by images in the luminous world.
While the elegant structural studies of
Lee et al. provide a spectacular glimpse
of the EBOV glycoprotein, the hard work
of exploiting this foundation for the devel-
opment of safe and effective vaccines and
therapeutics to one of the most patho-
genic viruses known to humans is still
ahead.An Ungracious Ho
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Persistence of latently infected CD4
retroviral therapies. In Cell Host & M
dissect the influence of host genes o
conclusions.
HIV-1 latency is established when a small
subset of CD4+ lymphoblasts exit the cell
cycle after proviral integration into the ge-
nome (Finzi et al., 1999). This long-lived
cell population harbours aHIV-1 reservoir,
where replication-competent provirus
retains the ability to reactivate into pro-
ductive infection while remaining shielded
from the immune system by effective
and reversible silencing. Latently infected
cells are inadvertently maintained by
a suboptimal cellular environment for
HIV-1expression, including severalmech-
anisms (Marcello, 2006) operating at post-
transcriptional (i.e, inefficient viral mRNA
transport, inhibitory miRNAs) and tran-
scriptional levels (i.e., absence of cellular
[Sp1, NF-kB] and viral [Tat] activators; re-
pressive chromatin environment). These
processes are of interest given their po-
tential to be manipulated to render latent
HIV-1 susceptible to antiretroviral therapy.
An alternative transcriptional basis for
latency arose from studies indicatingREFERENCES
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this issue of Cell Host & Microbe, studies
by Lenasi and colleagues (Lenasi et al.,
2008) and Han and colleagues (Han
et al., 2008) utilize model systems to de-
termine if host genes play a contributing
role in maintaining proviral latency.
Lenasi and colleagues investigated
whether host gene TI mediates HIV-1 si-
lencing by using two clonal cell lines iso-
lated from an established Jurkat CD4+
T cell model of postintegration latency
(Jordan et al., 2003). Both clones contain
GFP-labeled HIV-1 integrated in a single
allele of a constitutively expressed host
gene (protein phosphatase 5 gene [PP5]
and SUMO-activating enzyme subunit-2
[UBA2]; Figure 1A). In unstimulated cells,
the authors demonstrate through quanti-
tative RT-PCR and chromatin immuno-
precipitation (ChIP) analysis that elon-
gating RNA polymerase (RNAPII-Ser2)
resided over the 50LTR and was accom-
panied by a concurrent depletion of Sp1
(a transcription factor indicating PIC
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